LOS ANGELES, March 18, 2005 (PRIMEZONE) -- Universal Detection Technology (OTCBB:UDTT) today announced that it has entered into a distribution agreement with Quantum Automation to exclusively sell and distribute UDTT's bacterial spore monitors in Singapore, Malaysia and Thailand. According to the terms of the deal Quantum Automation will purchase one of UDTT's anthrax detectors for demonstration and training purposes.
Working in collaboration with NASA's Jet Propulsion Laboratory (JPL), Universal Detection has developed bacterial spore detectors based on a chemical identification process created by JPL's Planetary Protection Unit. The device provides continuous and unattended detection of bacterial spores. If an elevated spore count is detected, an alarm notifies internal security on site as well as local emergency services via the device's landline or wireless networking capability. The device's response time is 15 minutes, which management believes is fast enough to help prevent widespread contamination and save lives.
"Quantum Automation has active presence in the Southeast Asian market and possesses an experienced team of experts in design, installation, and maintenance of building control systems," said Universal Detection's new head of Strategic Development Mr. Nima Montazeri. "We intend to utilize Quantum Automation's strength and market presence to launch an aggressive campaign to place UDTT's detector units in government and private buildings in Singapore, Malaysia, and Thailand. Our deal with Quantum Automation is one in a series of deals that we are working on generating with international partners around the globe for installation and monitoring of our detectors."
"At Quantum Automation Pte. Ltd., established in 1979, we are the leading specialists in intelligent building management systems, terrorism threat evaluation, and high-end security monitoring and control systems in the Southeast Asian region. We are honored that UDTT has selected us as their exclusive partner in the region in order to promote the state of the art bacterial spore detection technology. With the prevailing security threat in the region we believe that UDTT's detectors, as the first of its kind, is positioned to take the market by storm bringing about mutual benefits for our partnership with Universal Detection Technology," said Mr. Jimmy Chau, managing director of Quantum Automation.
About Universal Detection Technology
Universal Detection Technology (UDT), founded in 1973, is a developer of monitoring technologies, including bio-terrorism detection devices. Management believes that the Company's technology, together with third party technologies and devices, has positioned it to capitalize on growth and value opportunities related to Homeland Security. UDT, in cooperation with NASA's Jet Propulsion Laboratory (JPL), has developed a bio-terror `smoke' detector, which combines JPL's spore detection technology with UDT's aerosol capture device.
For more information, please visit http://udtt.invrel.net or http://www.udetection.com.
About Quantum Automation
Quantum Automation is technology solutions provider and has been in the business of engineering, design, system installation, commissioning, and maintenance services of electrical and mechanical equipment and building control systems since 1979. Quantum Automation has extensive experience in the field of building controls and has the capacity of offering consultants and developers total turnkey solutions for individual projects from beginning to end.
For more information about Quantum Automation please visit their website at http://www.qa.com.sg.
Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties include, among other things, the funding of amounts of capital adequate to provide for our working capital needs and our timely repayment of debt, our ability to timely and cost effectively complete the development and testing of our products targeted to the bio-chemical and medical markets, our ability to commercially produce our products on a profitable basis, commercial acceptance of our products, product price volatility, product demand, market competition and general economic conditions, and other factors described in the Company's filings with the Securities and Exchange Commission. We undertake no obligation and do not intend to revise or update publicly any forward looking statements for any reason.